Jason Comander
Ophthalmology · Boston, MANPI 1538211289
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,920 of the $10,701 with a category attached, or 92.7%. Biogen accounts for 92.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $9,937 and has fallen 99.7% since, to $32 in 2024.
Across 17 payments — averaging $629.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$10K
- Spark Therapeutics, Inc.$330
- Alcon$225
- Janssen Global Services, LLC$114
- Carl Zeiss Meditec, Inc.$70
- Novartis$23
- plus $18 from 1 others
Across 12 payments — averaging $5816.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spark Therapeutics, Inc.$70K
- AbbVie$11
What the payments were for
- Consulting fees$9,92093%
- Food & beverage$7637%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $9,920 |
| Spark Therapeutics, Inc. | 5 | $330 |
| Alcon | 2 | $225 |
| Janssen Global Services, LLC | 1 | $114 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Novartis | 1 | $23 |
| Travere Therapeutics, Inc. | 5 | $18 |
How this compares
$10,701 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.